Category Archives: HIV care & treatment

Project Inform announces new Covered CA Plan Guide & Formulary analysis


Project Inform and several other community partners today released the guide, “How to Choose a Health Plan in Covered California”, for people living with HIV and/or hepatitis C (HCV) and individuals considering pre-exposure prophylaxis (PrEP). The guide explains important things to consider when choosing a plan…Read More

Stop CPMC from Dismantling Health Services for HIV Patients in San Francisco!


ACTION ALERT.   ONLINE PETITION. California Pacific Medical Center (CPMC) recently took steps to close the Davies Campus AIDS Case Management program and outsource its systems navigation for HIV clients to a contractor. This move involves layoffs for a highly-experienced team: Medical Social Worker, Laila Hinkle and…Read More



As members of the SF Health Care Reform TF, we know that now is not the time to lose two dedicated and experienced case managers and program enrollment workers who have helped hundreds of San Franciscans living with HIV access the life-saving care and treatment they…Read More

Join us for a community forum on World AIDS Day


WORLD AIDS DAY FORUM: Getting to Zero in San Francisco … Progress and Plans Presented by the Getting to Zero Consortium* Monday, December 1, 2014, 6:30 to 8:30 pm San Francisco Department of Public Health 25 Van Ness Ave., 6th Floor The event is free and open to…Read More

Experimental HIV drug doravirine shows fewer side effects in study


At the 12th International Congress on HIV Drug Therapy in Glasgow, Scotland, early 48-week data were released November 3, 2014 from a planned 96-week study of the NNRTI called doravirine in people new to HIV treatment. The Phase IIb study compared doravirine vs efavirenz (Sustiva), both…Read More

New HIV genotype test can find drug resistance even at undetectable viral loads


Announced on October 20, 2014, a new test has now become available that can detect HIV drug resistance in people with very low or undetectable viral loads. This will help clinicians and patients choose the most potent drugs for people with HIV-1 infection. Up to now,…Read More

FDA approves two new doses of elvitegravir, in addition to its current use in Stribild


On September 24, 2014, the FDA approved two new standalone doses of the integrase inhibitor elvitegravir, which now comes with the brand name Vitekta. The 85mg dose can be taken with Reyataz (atazanavir) and Kaletra (lopinavir), while the 150mg dose can be taken with Prezista (darunavir),…Read More